The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Experimental research

A perlecan-inducing compound significantly inhibits smooth muscle cell function and in-stent intimal hyperplasia: novel insights into the diverse biological effects of perlecan

EuroIntervention 2010;6:134-140.

1. The Roy and Ann Foss Cardiovascular Research Program, Terrence Donnelly Heart Center, St. Michael’s Hospital, University of Toronto, Toronto, Ontario, Canada; 2. The Heart Institute, Chaim Sheba Medical Center, Tel Hashomer, Sackler School of Medicine,

Aims: Perlecan is the major heparan sulfate proteoglycan in the arterial wall. Previous studies have suggested that perlecan is a potent inhibitor of smooth muscle cell (SMC) activity. Ther

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article
Micro-computed tomographic assessment following extremely oversized partial postdilatation of drug-eluting stents